Compare BEKE & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEKE | MEDP |
|---|---|---|
| Founded | 2001 | 1992 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 17.2B |
| IPO Year | 2020 | 2016 |
| Metric | BEKE | MEDP |
|---|---|---|
| Price | $16.41 | $615.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 12 |
| Target Price | $23.70 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 4.7M | 188.9K |
| Earning Date | 05-21-2026 | 04-22-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 8.53 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.19 |
| Revenue Next Year | $6.98 | $7.75 |
| P/E Ratio | ★ $41.26 | $72.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.81 | $373.00 |
| 52 Week High | $20.65 | $677.90 |
| Indicator | BEKE | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 56.15 |
| Support Level | $15.77 | $561.82 |
| Resistance Level | $16.81 | $629.30 |
| Average True Range (ATR) | 0.32 | 14.25 |
| MACD | -0.04 | 0.75 |
| Stochastic Oscillator | 33.23 | 62.87 |
KE Holdings, or Beike, is a large residential real estate sales and rental brokerage company in China. Founded in 2001, the company operates through self-owned Lianjia stores in Beijing and Shanghai and connected third-party agencies, including franchise brand Deyou in other cities, with commissions charged on existing-home and new-home transactions. Leveraging an online-offline hybrid model, Beike also attract clients through its namesake online marketplace. The company tapped into home renovation services by acquiring Shengdu Home Decoration in 2022. As of the end of 2025, Beike's co-founders collectively control the company, while Tencent and its affiliates share 8% of voting power.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.